Brief: Paratek Pharmaceuticals Announces Positive Data From Pilot Efficacy Study For The Treatment Of Pulmonary Anthrax
19/12/2022 12:34
Dec 19 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK PHARMACEUTICALS ANNOUNCES POSITIVE TOP LINE DATA
FROM
PILOT EFFICACY STUDY FOR THE TREATMENT OF PULMONARY ANTHRAX AND
ACCEPTANCE OF THE SECOND PROCUREMENT OF NUZYRA® (OMADACYCLINE)
UNDER BARDA PROJECT BIOSHIELD
Source text for Eikon: ID:nGNX2ylr8h
Further company coverage: PRTK.O
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million